Search results
Jun 29, 2015 · Celgene Corp on Monday launched a 10-year partnership with Juno Therapeutics, announcing a $1 billion investment aimed at bringing to market Juno technologies that harness the immune system to treat cancer and autoimmune diseases. The huge vote of confidence propelled Juno's shares more than 40 percent higher to $65.75 in heavy extended trading. Celgene will pay Juno about $150 million upfront ...
- Dive Brief
- Dive Insight
- Doubling Down on Multiple Myeloma
- Tax Reform Boost
Celgene Corp. will acquire Juno Therapeutics Inc. and its pipeline of cancer cell therapies for $9 billion, betting on the continued emergence of CAR-T at a time when concerns over future growth ha...At a takeout price of $87 per share, the deal values Juno at a nearly 91% premium to the company’s share price before a reportfrom The Wall Street Journal indicated Celgene was in talks to buy the...Acquiring Juno hands Celgene full ownership of JCAR017, a CAR-T therapy in pivotal clinical testing for a type of lymphoma. Celgene expects to win U.S. approval for the treatment in 2019, positioni...Celgene already had a sizable interest in the CAR-T space, having previously inked partnerships with Juno and bluebird bio Inc. to develop cell therapies targeting CD19 and the B-cell maturation antigen (BCMA). In that sense, buying Juno is a logical next step that capitalizes on the emerging profile for Juno’s lead asset JCAR017 and its earlier ca...
Another key driver behind Juno’s interest in acquiring Juno is the company’s development of a CAR-T candidate targeting BCMA for treatment of multiple myeloma. JCARH125, as it’s known, remains very early-stage at this point. But clinical data on anti-BCMA candidates for multiple myeloma, particularly from Celgene’s partner bluebird bio, have widely...
Industry investors have been eager to see what impact the recently enacted tax reform package will have on industry M&A. Many biopharmas hold large piles of cash off shore to avoid paying high U.S. corporate taxes. With statutory rates now lowered, those companies will pay much less to use those financial resources domestically — sparking predictio...
People also ask
Will Celgene buy Juno Therapeutics?
Why did Celgene & Juno share price rise 40 percent?
Who are Juno Therapeutics co-founders?
How much will Celgene pay Juno?
Feb 8, 2022 · When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune cells ...
Mar 1, 2017 · Shares of biotech company Juno Therapeutics fell nearly 8 per cent on Wednesday after it formally pulled the plug on development of a prospective cancer treatment following five patient deaths.
Jan 22, 2018 · Bishop, one of Juno's founders, is set to collect more than $200 million from the deal. As of last week, he held about 2.5 million shares, according to Nasdaq. At the $87-per-share price Celgene ...
- Eric Sagonowsky
Sep 11, 2015 · However, while I agree with the author that Juno will essentially raise about a billion in capital via Celgene purchases of Juno stock at $93/share, I don't agree that the remainder of the deal ...
Feb 4, 2015 · The hype surrounding Juno Therapeutics and why it has been able to raise a ton of money quickly has a lot to do with its big name founders and management. By far, Juno has the most impressive team ...
